Daniel Kastner has been selected as the scientific director of the National Human Genome Research Institute and will take up his post in early October. He is currently the clinical director and the director of translational research at the National Institute of Arthritis and Musculoskeletal and Skin Diseases. At NHGRI, Kastner will lead the division of intramural research. He joined NIAMS as a research fellow in 1987 and became a senior staff fellow in 1990. He then became acting chief and later chief of the genetics section of the arthritis and rheumatism branch, which was later converted into the genetics and genomics branch. He holds a PhD and medical degree from Baylor College of Medicine and an AB in philosophy from Princeton University.
Harry Hixson, CEO of Sequenom, has resigned from the board of directors of NovaBay Pharmaceuticals due to his increasing executive responsibilities at Sequenom. He had served as a NovaBay director since early 2009.